Pulmonary manifestations, treatments and outcomes of IgG4-related disease–a systematic literature review
Rheumatology International · 2024
DOI: 10.1007/s00296-024-05611-7 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Rheumatology International, 2024. Verfasst von Cristina Dragos und 4 weiteren Autor:innen. Beteiligte Einrichtung: Liverpool University NHS Foundation Trust, Prescot Street, Liverpool, L7 8XP, UK. Hauptthemen laut MEDLINE: Immunoglobulin G4-Related Disease, Immunosuppressive Agents, Lung Diseases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immunoglobulin G4–related disease (IgG4-RD) is a multisystem fibroinflammatory condition. A consistent feature of many cases is pulmonary infiltrates, or respiratory failure. This systematic literature review aims to summarise the pulmonary manifestations of IgG4-RD, including clinical outcomes and treatment. This review was registered on PROSPERO (CRD42023416410). Medline, Embase and Cochrane databases were searched for articles discussing IgG4-RD syndrome. Information was extracted on demographics, type and prevalence of pulmonary manifestations, treatment and clinical outcomes. Initially, after deduplication, 3123 articles were retrieved with 18 ultimately included. A pooled total of 724 patients with IgG4-RD were included, 68.6% male, mean age 59.4 years (SD 5.8) at disease onset. The most frequently described pulmonary manifestation was mediastinal lymphadenopathy (n = 186, 48.8%), followed by pulmonary nodules (n = 151, 39.6%) and broncho-vascular thickening (n = 85, 22.3%). Where treatment was reported, the majority of patients received glucocorticoids (n = 211, 93.4%). Other immunosuppressive therapy included cyclophosphamide (n = 31), azathioprine (n = 18), with mycophenolate mofetil (n = 6), rituximab (n = 6), methotrexate (n = 5) and other unspecified immunomodulators (50). Clinical outcomes were reported in 263 patients, where 196 patients had remission of their disease, 20 had relapse, 35 had stable disease, four had progression and eight patients died from complications of IgG4-RD. This systematic review summarises pulmonary manifestations, treatments and outcomes in patients with IgG4-RD. Pulmonary involvement in IgG4-RD is relatively common, leading to high levels of morbidity and mortality. Glucocorticoids remain the mainstay of treatment, but further work is required to explore the management of patients with pulmonary manifestations in association with IgG4-RD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liverpool University NHS Foundation Trust, Prescot Street, Liverpool, L7 8XP, UK.
- British Medical Association Library, BMA House, Tavistock Square, London, WC1H 9JP, UK.
- Centre for Rheumatic Diseases, Weston Education Centre, Cutcombe Road, London, SE5 9RJ, UK.
- School of Medicine, Cedar House, University of Liverpool, Ashton Street, Liverpool, L69 3GE, UK. k.kouranloo2@liverpool.ac.uk.
- Department of Rheumatology, University Hospital Lewisham, High Street, Lewisham, London, SE13 6LH, UK. k.kouranloo2@liverpool.ac.uk.
ORCID-Profile: Cristina Dragos, Clerin Joseph, Helen Elwell, Mrinalini Dey, Koushan Kouranloo
Zitieren
APA
Dragos, C., Joseph, C., Elwell, H., Dey, M., & Kouranloo, K. (2024). Pulmonary manifestations, treatments and outcomes of IgG4-related disease–a systematic literature review. Rheumatology International. https://doi.org/10.1007/s00296-024-05611-7
Vancouver
Dragos C, Joseph C, Elwell H, Dey M, Kouranloo K. Pulmonary manifestations, treatments and outcomes of IgG4-related disease–a systematic literature review. Rheumatology International. 2024. doi:10.1007/s00296-024-05611-7
BibTeX
@article{Dragos2024,
author = {Dragos, Cristina and Joseph, Clerin and Elwell, Helen and Dey, Mrinalini and Kouranloo, Koushan},
title = {Pulmonary manifestations, treatments and outcomes of IgG4-related disease–a systematic literature review},
journal = {Rheumatology International},
year = {2024},
doi = {10.1007/s00296-024-05611-7}
}
EUVIMED